Alzheimer's Disease Trial, By Invitation NCT06817902 Sponsor: HealthPartners Institute Condition: Alzheimer's Disease
Back to Alzheimers Disease

Alzheimer's Disease Trial, By Invitation

NCT06817902
By Invitation Not Applicable

voxsanity.com.au · Eligibility summary from public government registries · 18 August 2026 · not medical advice

Who may and may not be able to join

AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI

Who may be able to join

  • People who have been diagnosed with Mild Cognitive Impairment (MCI) or mild Alzheimer's disease.
  • People who have test results (such as a brain scan or fluid sample from around the spine) showing signs of amyloid protein buildup in the brain, which is associated with Alzheimer's disease.
  • People who have already had a brain imaging scan performed.
  • People who scored higher than 24 on a standard memory and thinking test called the Mini Mental Status Examination (MMSE).
  • People who have a Clinical Dementia Rating (CDR) score of 0.5 to 1, which indicates very mild to mild impairment (confirm with trial site).
  • People who have been taking memory-related medications (cholinesterase inhibitors and/or memantine) at the same dose for at least one month.
  • People who are between 40 and 90 years of age.

Who may not be able to join

Each point below is a reason the trial team may not be able to accept someone. It is not a list of requirements to meet.

  • People who have a type of dementia other than Alzheimer's disease, such as Lewy body dementia, frontotemporal dementia, vascular dementia, or Jakob-Creutzfeldt disease, among others.
  • People who are unable to tolerate a specific type of brain scan called a resting state functional MRI (rs-fMRI).
  • People who have implants or metal in their body that make it unsafe to have an MRI scan.
  • People who have a seizure disorder (epilepsy or a history of seizures).

Important: Always verify eligibility with the trial site directly before applying.

Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.

This is a simplified plain English summary of the eligibility criteria. Full criteria are set by the trial investigators and may include additional requirements not shown here. Never self-exclude from a trial based on this summary. Contact the trial site directly to confirm your eligibility.
Last synced 18 August 2026
This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.

GP referral letter

Print a one-page summary to share with your doctor.

Trial details

Status
By Invitation
Phase
Not Applicable
Sponsor
HealthPartners Institute
Registry
ClinicalTrials.gov
Start date
23 December 2024
Est. completion
1 December 2026

Where this trial is recruiting

🇺🇸 United States

Primary endpoints

Effect of TBS on cognition between and within subjects using Repeatable Battery for the Assessment of Neuropsychological Status Update (RBANS)

Can't join this trial?

Expanded access pathways

If this trial is not available to you, other access pathways may exist. In Australia, the TGA Special Access Scheme allows access to unapproved therapeutic goods for individual patients.

TGA Special Access Scheme information

Find other recruiting trials on ClinicalTrials.gov

Data last synced from ClinicalTrials.gov: 18 August 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.

Trial recruitment status can change without notice between our nightly data updates. Always contact the trial site directly to confirm current recruitment status before making any decisions or travel arrangements.

View original record on ClinicalTrials.gov